Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ORIC Pharmaceuticals stock

Own ORIC Pharmaceuticals stock in just a few minutes.

ORIC Pharmaceuticals, Inc is a biotechnology business based in the US. ORIC Pharmaceuticals shares (ORIC) are listed on the NASDAQ and all prices are listed in US Dollars. ORIC Pharmaceuticals employs 61 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in ORIC Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ORIC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ORIC Pharmaceuticals share price

Use our graph to track the performance of ORIC stocks over time.

ORIC Pharmaceuticals shares at a glance

Information last updated 2021-04-21.
52-week range$18.60 - $40.81
50-day moving average $26.21
200-day moving average $29.40
Wall St. target price$44.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy ORIC Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ORIC Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ORIC Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -15.69%
Return on equity TTM -39.02%
Profit margin 0%
Book value N/A
Market capitalisation $772.8 million

TTM: trailing 12 months

Shorting ORIC Pharmaceuticals shares

There are currently 4.8 million ORIC Pharmaceuticals shares held short by investors – that's known as ORIC Pharmaceuticals's "short interest". This figure is 31.6% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting ORIC Pharmaceuticals shares can be evaluated.

ORIC Pharmaceuticals's "short interest ratio" (SIR)

ORIC Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ORIC Pharmaceuticals shares currently shorted divided by the average quantity of ORIC Pharmaceuticals shares traded daily (recently around 310260.44386423). ORIC Pharmaceuticals's SIR currently stands at 15.32. In other words for every 100,000 ORIC Pharmaceuticals shares traded daily on the market, roughly 15320 shares are currently held short.

However ORIC Pharmaceuticals's short interest can also be evaluated against the total number of ORIC Pharmaceuticals shares, or, against the total number of tradable ORIC Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ORIC Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 ORIC Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1905% of the tradable shares (for every 100,000 tradable ORIC Pharmaceuticals shares, roughly 191 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ORIC Pharmaceuticals.

Find out more about how you can short ORIC Pharmaceuticals stock.

ORIC Pharmaceuticals share dividends

We're not expecting ORIC Pharmaceuticals to pay a dividend over the next 12 months.

ORIC Pharmaceuticals overview

ORIC Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Astellas Pharma, Inc. ; Voronoi, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site